A new drug similar to one that helps women ovulate could be beneficial in treating symptoms of low testosterone in men without increased risk of severe side effects. The drug, called enclomiphene citrate, helps the body produce more testosterone on its own, whereas testosterone boosters and “Low T” drugs replace the hormone.
The drug is in the second phase of a 4-phase clinical trial to determine safety and efficacy before being sent to the U.S. Food and Drug Administration for approval. Testosterone boosters currently on the market, such as AndroGel and AndroDerm, have come under recent scrutiny after a medical study found that the drugs were linked to an increased risk of heart attacks. Testosterone levels in the body also decrease drastically after use of Low T drugs is stopped.
Some medical experts urge caution with the use of current testosterone boosters, as many patients who are prescribed them may not have undergone significant clinical testing to determine a need for testosterone. Doctors have also criticized medical companies for advertising common conditions of aging in middle-aged men as testosterone deficiency, which may lead patients to seek out potentially dangerous drugs for low-risk conditions such as fatigue and low libido.